Our new report will show you how the market for antithrombotic and anticoagulant drugs will develop. You can indentify where the greatest opportunities will lie. There will be trends to watch from 2010 onwards, especially product launches and areas of revenue growth. You can have our report today, staying ahead.


We show how you can benefit from the sector's developments and potential. There remain unmet therapeutic needs. New drugs with improved safety and efficacy can gain significant market shares from 2010 onwards. Novel and generic drug producers can benefit from this sector from 2010 to 2025, as our new report shows and explains.


Antithrombotic/Anticoagulant Drugs: World Market Prospects 2010-2025 covers the following therapeutic categories:

• Platelet aggregation inhibitors
• Heparins
• Fibrinolytics
• Vitamin K antagonists
• Direct thrombin inhibitors
• Other agents.

What therapeutic agents are likely to enter the market from 2010 onwards, and can they dominate? Where will the best commercial opportunities lie? How will industry/market drivers and restraints affect the sector? We show you commercial opportunities and challenges for the sector, especially revenue trends for 2010 to 2025.

You will discover commercial prospects at global, national, sub-market and product levels. You can assess the sector's potential today. We aim to save you time and benefit your work.


Industry and market analysis to save you time and aid your decisions


Our new report examines the antithrombotic and anticoagulant sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses, pipeline developments and other data. You can discover strengths, weaknesses, opportunities and threats in the sector. We include many tables and figures and an expert interview - shown in the contents lists with this message.


Report Highlights
Companies Listed
Ablynx
Acino Pharma
Amphastar Pharmaceuticals
Apotex
ARCA Discovery
Archemix
Arena Pharmaceuticals
ARYx Therapeutics
AstraZeneca
Barr Pharmaceuticals (now a part of Teva)
Bayer HealthCare
Bayer Schering Pharma
Berlex Pharmaceuticals
Bharat Pharma
BioInvent
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Cardiome Pharma
Daiichi Sankyo
Dainippon Sumitomo Pharma
deCODE genetics
Eisai Pharmaceuticals
Eli Lilly and Company
Endotis Pharma
European Medicines Agency (EMA/EMEA)
Food and Drug Administration (US FDA)
Genentech
GlaxoSmithKline (GSK)
Hexal
Indigo Pharmaceuticals
Japanese Society for Spine Surgery and Related Research
Johnson & Johnson
Kyowa Hakko
Ligand Pharmaceuticals
Lundbeck
Merck & Co.
Mitsubishi Kasei
Momenta Pharmaceuticals
Myriad Genetics
New England Journal of Medicine
Nissan Chemical
Novartis
Ono Pharmaceutical Co.
Organon (now part of Merck & Co.)
Otsuka Pharmaceuticals
PAION
ParinGenix
Pfizer
Pharmacia (acquired by Pfizer in 2002)
Portola Pharmaceuticals
POZEN
Ranbaxy (now part of Daiichi Sankyo)
ratiopharm
Roche
ROVI Pharmaceuticals
Sanofi-Aventis
Servier Laboratories
Taisho Pharmaceutical Co.
Talecris Biotherapeutics
Teva Pharmaceutical Industries
The Aptamer Therapeutics Company
The Medicines Company
The US Federal Trade Commission
ThromboGenics
Trigen Pharma
University of Nottingham, UK
Vernalis Pharmaceuticals
Watson Pharmaceuticals
[Studien Infos ausblenden]

Table 4.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2016
Table 4.2 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2017-2025
Table 4.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Sales ($bn) and Market Shares (%), 2009
Table 4.4 Leading Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2010-2016
Table 4.5 Leading Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2017-2025
Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2009
Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2016
Table 5.3 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2017-2025
Table 5.4 Plavix Sales Forecast ($m), 2010-2016
Table 5.5 Plavix Sales Forecast ($m), 2017-2025
Table 5.6 Lovenox Sales Forecast ($m), 2010-2016
Table 5.7 Lovenox Sales Forecast ($m), 2017-2025
Table 5.8 Pletaal Sales Forecast ($m), 2010-2016
Table 5.9 Pletaal Sales Forecast ($m), 2017-2025
Table 5.10 Asasantin Sales Forecast ($m), 2010-2016
Table 5.11 Asasantin Sales Forecast ($m), 2017-2025
Table 5.12 Fragmin Sales Forecast ($m), 2010-2016
Table 5.13 Fragmin Sales Forecast ($m), 2017-2025
Table 5.14 Opalmon Sales Forecast ($m), 2010-2016
Table 5.15 Opalmon Sales Forecast ($m), 2017-2025
Table 5.16 Aspirin Cardio Sales Forecast ($m), 2010-2016
Table 5.17 Aspirin Cardio Sales Forecast ($m), 2017-2025
Table 5.18 Angiomax Sales Forecast ($m), 2010-2016
Table 5.19 Angiomax Sales Forecast ($m), 2017-2025
Table 5.20 Arixtra Sales Forecast ($m), 2010-2016
Table 5.21 Arixtra Sales Forecast ($m), 2017-2025
Table 5.22 Activase Sales Forecast ($m), 2010-2016
Table 5.23 Activase Sales Forecast ($m), 2017-2025
Table 6.1 SWOT Analysis: Anticoagulant/Antithrombotic Drug Market, 2010
Table 7.1 Late-Stage Platelet Aggregation Inhibitors R&D Pipeline, 2010
Table 7.2 Late-Stage Heparin Drugs R&D Pipeline, 2010
Table 7.3 Late-Stage Fibrinolytics R&D Pipeline, 2010
Table 7.4 Late-Stage Direct Thrombin Inhibitors R&D Pipeline, 2010
Table 7.5 R&D Pipeline for Other Antithrombotic/Anticoagulant Drugs, 2010
Table 8.1 Leading National Markets for Antithrombotic/Anticoagulant Drugs ($bn), 2009
Table 8.2 Leading National Markets for Antithrombotic/Anticoagulant Drugs: Forecasts ($bn), 2010-2016
Table 8.3 Leading National Markets for Antithrombotic/Anticoagulant Drugs: Forecasts ($bn), 2017-2025
Table 8.4 Leading National Markets: Market Shares (%), 2009, 2015, 2020 & 2025
Table 10.1 Antithrombotic/Anticoagulant Drug Market ($bn), 2009, 2015, 2020 & 2025

Figure 4.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2025
Figure 4.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2009
Figure 4.3 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2025
Figure 4.4 Heparins: Market Forecast ($bn), 2010-2025
Figure 4.5 Fibrinolytics: Market Forecast ($bn), 2010-2025
Figure 4.6 Vitamin K Antagonists: Market Forecast ($bn), 2010-2025
Figure 4.7 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2025
Figure 4.8 Leading Antithrombotic/Anticoagulant Therapeutic Classes ($bn), 2009, 2015 & 2025
Figure 5.1 Leading Antithrombotic/Anticoagulant Drugs: Market Shares (%), 2009
Figure 5.2 Plavix Sales Forecast ($m), 2010-2025
Figure 5.3 Lovenox Sales Forecast ($m), 2010-2025
Figure 5.4 Pletaal Sales Forecast ($m), 2010-2025
Figure 5.5 Asasantin Sales Forecast ($m), 2010-2025
Figure 5.6 Fragmin Sales Forecast ($m), 2010-2025
Figure 5.7 Opalmon Sales Forecast ($m), 2010-2025
Figure 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2025
Figure 5.9 Angiomax Sales Forecast ($m), 2010-2025
Figure 5.10 Arixtra Sales Forecast ($m), 2010-2025
Figure 5.11 Activase Sales Forecast ($m), 2010-2025
Figure 8.1 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2009
Figure 8.2 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2015
Figure 8.3 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2020
Figure 8.4 Antithrombotic/Anticoagulant Drug Market Shares by Country (%), 2025
Figure 8.5 The US Antithrombotic/Anticoagulant Drug Market ($bn), 2010-2025
Figure 8.6 The Japanese Antithrombotic/Anticoagulant Drug Market ($bn), 2010-2025
Figure 8.7 Leading Antithrombotic/Anticoagulant Drug Markets in Europe ($bn), 2010-2025
Figure 8.8 The Antithrombotic/Anticoagulant Drug Market in China & India ($bn), 2010-2025
Figure 10.1 The Antithrombotic/Anticoagulant Market: Sales ($bn), 2010-2025
Figure 10.2 Leading Therapeutic Classes: Sales ($bn), 2010-2025
Figure 10.3 Leading Products: Sales ($m), 2009, 2015 & 2025
Figure 10.4 Leading National Markets: Sales ($bn), 2009, 2015 & 2025
[Tabellenverzeichnis ausblenden]